TwitterYouTubeLinkedInEmail

Video

17 Aug, 2018

Xtalks Webinar: Neoantigens for Personalized Cancer Vaccines-Comprehensive Identification and Effective Selection

Xtalks Webinar Neoantigens for Personalized Cancer Vaccines-Comprehensive Identification and Effective Selection Developing effective personalized cancer vaccines depends on comprehensively detecting all neoantigens in a tumor sample and then selecting the neoantigens that are most likely to be effective in an individual patient.   This process, especially under the timeline demands of clinical trials or [...]

Read More
3 Jul, 2018

ACE ImmunoID for Biomarker Discovery

ACE ImmunoID for Biomarker Discovery Maximize your data for translational research. ACE ImmunoID integrates exome and transcriptome data to provide insights into: Mechanisms of immune escape The tumor microenvironment, and Tumor-specific neoantigens

Read More
3 Jul, 2018

Xtalks webinar: Overcoming the Challenges of Immuno-Oncology Biomarker Discovery From Sample to Analytics

Xtalks webinar: Overcoming the Challenges of Immuno-Oncology Biomarker Discovery From Sample to Analytics Only 20% of patients respond to cancer immunotherapies and determining which patients will respond to which treatment options relies on the identification of predictive biomarkers. Immuno-oncology biomarkers such as tumor mutational burden (TMB) or PD-L1 expression are promising, but have [...]

Read More
23 Jan, 2017

Comprehensive Tumor Characterization for Immuno Oncology, Clinical Trials, and Cancer Research

GenomeWeb: Comprehensive Tumor Characterization for Immuno Oncology, Clinical Trials, and Cancer Research This GenomeWeb seminar outlines a targeted enrichment technology to improve next-generation sequencing assays for cancer research and clinical applications. Presenters: Richard Chen, MD and Michael James Clark, PhD More Info: NGS is increasingly being used to support cancer clinical trials, translational [...]

Read More
23 Jan, 2017

ACE Augmentation Achieves High-Sensitivity for Clinical Applications 

ACE Augmentation Achieves High-Sensitivity for Clinical Applications Heather Wetzel, MS, LCGC discusses the recent publication in Genome Medicine entitled "Achieving high-sensitivity for clinical applications using augmented exome sequencing". Heather will review the results from this first ever comparison of an augmented exome sequencing approach (ACE Clinical Exome) to other standard exomes and whole [...]

Read More
19 Jan, 2017

AMP Webinar: Achieving High Diagnostic Yield for Clinically Relevant Genes

AMP Webinar: Achieving High Diagnostic Yield for Clinically Relevant Genes Heather Wetzel, MS, LCGC discusses the recent publication in Genome Medicine entitled "Achieving highsensitivity for clinical applications using augmented exome sequencing". Heather discusses the results from this first ever comparison of an augmented exome sequencing approach (ACE Clinical Exome) to other standard exomes [...]

Read More
19 Jan, 2017

Labroots: ACE CancerPlus Test for DNA & RNA Sequencing for Improved Patient Outcomes

Labroots: ACE CancerPlus Test for DNA & RNA Sequencing for Improved Patient Outcomes Oncologists and pathologists are increasingly utilizing information on genomic alterations in tumors to help guide patient care and treatment. Personalis, Inc., a genomic sequencing and interpretation company, has developed a tumor-profiling test that provides clinicians with accurate and comprehensive analysis [...]

Read More
19 Jan, 2017

Labroots: Benefits & Burdens of Assaying Matched Normal Tissue when Sequencing Cancer Genomes 

Labroots: Benefits & Burdens of Assaying Matched Normal Tissue when Sequencing Cancer Genomes Targeted sequencing assays are increasingly used to identify tumor mutations that guide therapeutic decisions. Interpretation of a cancer variant’s origin and therapeutic impact poses analytical challenges. Recent studies have indicated that jointly analyzing a tumor with its matched normal can [...]

Read More